Atlas Trials

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

Clinical trial NCT07126236 · RECRUITING

Trial details

NCT number
NCT07126236
Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Large B Cell Lymphoma
Start date
2025-08-04
Primary completion
2031-12-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.